Opaleye Management Inc. Neoleukin Therapeutics, Inc. Transaction History

Opaleye Management Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.69 - $1.33 $24,149 - $46,550	-35,000 Reduced 5.74%	575,000 $368,000
Q2 2022 Aug 15, 2022	SELL	$0.92 - $2.25 $165,600 - $405,000	-180,000 Reduced 22.78%	610,000 $628,000
Q1 2022 May 16, 2022	SELL	$1.72 - $5.23 $442,556 - $1.35 Million	-257,300 Reduced 24.57%	790,000 $1.49 Million
Q3 2021 Nov 16, 2021	SELL	$6.05 - $9.66 $658,845 - $1.05 Million	-108,900 Reduced 9.42%	1,047,300 $7.57 Million
Q2 2021 Aug 16, 2021	SELL	$9.23 - $13.12 $635,024 - $902,656	-68,800 Reduced 5.62%	1,156,200 $10.7 Million
Q1 2021 May 18, 2021	SELL	$11.26 - $15.78 $1.82 Million - $2.55 Million	-161,300 Reduced 11.64%	1,225,000 $15.1 Million
Q3 2020 Nov 16, 2020	SELL	$9.68 - $17.01 $132,616 - $233,037	-13,700 Reduced 0.98%	1,386,300 $16.6 Million
Q1 2020 May 15, 2020	BUY	$6.12 - $13.64 $114,444 - $255,068	18,700 Added 1.35%	1,400,000 $15.9 Million
Q4 2019 Feb 14, 2020	BUY	$2.65 - $12.72 $1.02 Million - $4.91 Million	386,300 Added 38.82%	1,381,300 $17 Million
Q3 2019 Nov 14, 2019	BUY	$2.33 - $3.76 $2.32 Million - $3.74 Million	995,000 New	995,000 $2.84 Million

199K

Ticker NLTX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 42,579,900
Description
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of vario...

Get notified when there are updates to the investment portfolio of Opaleye Management Inc., based on Form 13F filings with the SEC.

Stay updated on Opaleye Management Inc. with notifications on news.